The new treatment technique is specific to cancers that express the protein EGFRvIII. Roughly a third of all glioblastomas -- the most common and aggressive type of brain tumor -- feature EGFRvIII. Tumors that express the protein tend to be the most aggressive and the most resistant to traditional treatments.
The unique treatment begins with the extraction of blood from the cancer patient. The sample's T cells, the body's main blood-bound immune cell, are isolated and trained to hunt down a specific protein via gene therapy.